May 31, 2018 08:24 AM EDT
R&D

Madri­gal shares soar on promis­ing PhII NASH da­ta, stok­ing hopes for a new con­tender

John Carroll

Editor & Founder

You can add Madri­gal Phar­ma­ceu­ti­cals $MDGL to your list of NASH con­tenders — and a soar­ing share price this morn­ing to un­der­score the block­buster mar­ket it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times